The future of targeted kinase inhibitors in melanoma

Keywords

Cancer

Melanoma

Targeted therapy

Kinase inhibitors

Immune checkpoint inhibitors

Combination therapy

AbbreviationsADCs

antibody-drug conjugates

AJCC

American Joint Committee on Cancer

AKT

Akt serine threonine kinase

AM

acral lentiginous cutaneous melanoma

BAP1

BRCA1 associated protein 1

BETi

Bromodomain and extra-terminal motif protein inhibitors

CDK4/6i

cyclin-dependent kinase-4/6 inhibitors

CM

cutaneous melanoma of the non-acral skin

CTLA-4

cytotoxic T-lymphocyte-associated protein 4

FAKi

focal adhesion kinase inhibitors

FDA

U.S. Food and Drug Administration

GPCR

G-protein-coupled receptor

HD-IL-2

high-dose interleukin-2

HDACi

histone deacetylase inhibitors

HGF

hepatocyte growth factor

ICi

immune checkpoint inhibitors

IGF1

insulin-like growth factor 1

LAG-3

lymphocyte activation gene 3

MAPK

mitogen-activated protein kinase

MHC

major histocompatibility complex

mTOR

mammalian target of rapamycin

PD-1

programmed death protein 1

PD-L1

programmed death ligand-1

PFS

progression-free survival

PI3K

phosphoinositide 3-kinase

PROTACs

proteolysis-targeting chimeras

RTKs

receptor tyrosine kinases

scRNA-seq

single-cell RNA-sequencing

TILs

tumor-infiltrating lymphocytes

TIME

tumor immune microenvironment

T-VEC

talimogene laherparepvec

留言 (0)

沒有登入
gif